Skip to main content
Smart Investors Daily
BC

NASDAQ · BCAX

Bicara Therapeutics Inc. Common Stock

Healthcare · Biotechnology

$9.75

Down-$0.27 (-2.69%)

Updated Nov 17, 2026, 5:33 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-10.02
Dividend yield
0.00%
52-week range
$7.87 – $30.99
Volume
1.1M
Avg. volume
676.71K

Price performance · BCAX

BCAX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

BCAX closed at $9.75 after 21 trading sessions, down 44.19% for the selected period.

Last close
$9.75
Period change
-44.19%
Period low
$7.93
Period high
$18.35
Daily close
View OHLC price history
BCAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$9.87$10.17$9.55$9.751.1M
Nov 13, 2026$9.96$10.14$9.71$10.021.52M
Nov 12, 2026$10.40$10.45$9.76$10.111.89M
Nov 11, 2026$10.35$11.45$10.1101$10.531.51M
Nov 10, 2026$9.76$10.33$9.4477$10.181.95M
Nov 9, 2026$8.90$10.07$8.65$9.981.83M
Nov 6, 2026$8.32$8.93$8.06$8.651.01M
Nov 5, 2026$8.82$8.90$8.15$8.191.11M
Nov 4, 2026$9.19$9.275$8.69$8.891.05M
Nov 3, 2026$8.03$9.48$7.90$8.962.33M
Nov 2, 2026$9.06$9.165$7.87$7.932.5M
Oct 30, 2026$9.38$9.38$8.36$9.134.2M
Oct 29, 2026$9.79$10.19$9.35$9.733.2M
Oct 28, 2026$17.37$17.57$8.90$9.7615.42M
Oct 27, 2026$16.91$17.59$16.60$17.48609.33K
Oct 26, 2026$16.98$17.67$16.44$16.891.05M
Oct 23, 2026$17.53$17.85$16.98$17.07730.16K
Oct 22, 2026$17.92$18.07$17.15$17.61816.94K
Oct 21, 2026$18.31$18.78$17.90$17.91656.72K
Oct 20, 2026$17.79$18.645$17.31$18.35493.42K
Oct 19, 2026$16.92$17.60$16.60$17.47865.42K

Latest BCAX news

The latest Smart Investors Daily articles mentioning BCAX.

BCAX research

Overview

Company profile and research snapshot.

Company profile

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$40.00
Implied upside
—
Analysts
—
BCAX recent ratings
DateFirmRatingTarget
Nov 11, 2026HC Wainwright & Co.Buy—
Nov 10, 2026StifelBuy—
Nov 10, 2026BTIGBuy—
Nov 10, 2026Morgan StanleyOverweight—
Oct 30, 2026Goldman SachsSell—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.